Compare RAYA & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAYA | LSTA |
|---|---|---|
| Founded | 2019 | 1980 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 20.9M |
| IPO Year | 2022 | N/A |
| Metric | RAYA | LSTA |
|---|---|---|
| Price | $4.20 | $2.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | ★ 32.8K | 23.0K |
| Earning Date | 04-17-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,101,325.00 | $1,070,000.00 |
| Revenue This Year | $20.95 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.78 | N/A |
| 52 Week Low | $3.13 | $1.81 |
| 52 Week High | $736.99 | $4.20 |
| Indicator | RAYA | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 49.89 | 49.24 |
| Support Level | $3.95 | $1.96 |
| Resistance Level | $4.50 | $2.10 |
| Average True Range (ATR) | 0.46 | 0.11 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 27.92 | 61.11 |
Erayak Power Solution Group Inc engages in manufacturing, research and development, and wholesale and retail of power solution products. Its product portfolio includes sine wave and off-grid inverters, inverter and gasoline generators, battery, and smart chargers, and custom-designed products. It derives the majority revenue from four products namely inverters, chargers, power bank, and gasoline generators. The company generates the majority of its revenue from Inverters. The company geographically operates in China, Australia, Poland, U.K., and Germany. It derives maximum revenue from China.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.